Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This phase II study found that gemcitabine plus paclitaxel showed promising activity and manageable toxicity as first-line therapy for recurrent or metastatic breast cancer, with a 35% overall response rate.

The combination of gemcitabine and vinorelbine is effective and safe for treating elderly patients with advanced breast cancer previously treated with anthracyclines and taxanes.

This study reported that a gemcitabine and pemetrexed regimen was moderately active in advanced NSCLC but did not offer an advantage over the paclitaxel and gemcitabine regimen and is not recommended for further evaluation.

The new chemotherapy combination for advanced lung cancer showed a 35.7% response rate but caused significant side effects.

In this study, pemetrexed combined with cisplatin for advanced NSCLC treatment had similar efficacy to gemcitabine but resulted in significantly fewer adverse reactions.